Ampersand provides more data to back InPath test
This article was originally published in Clinica
Executive Summary
Further evidence that Ampersand Medical's InPath slide-based test outperforms conventional Pap screening for cervical cancer was presented at the 14th International Congress of Cytology in Amsterdam, the Netherlands, at the end of May. Matthew Gombrich, senior scientist at Chicago, Illinois-based Ampersand, told delegates that in a study of 45 samples, the InPath test demonstrated 100% accuracy for detecting high-grade squamous intraepithelial lesions.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.